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ABSTRACT 
Objective: People with posttraumatic stress disorder (PTSD) have a higher mortality 
than the general population, mainly due to cardiovascular diseases (CVD). Metabolic 
syndrome (MetS) and its components are highly predictive of CVD. The aim of this 
meta-analysis was to describe pooled frequencies of MetS and its components in 
people with PTSD and to compare MetS prevalences in PTSD versus the general 
population. 
Method: Medline, PsycARTICLES, Embase and CINAHL were searched until 
02/2015 for cross-sectional and baseline data of longitudinal studies in adults with 
PTSD. Two independent reviewers conducted the searches and extracted data. 
Random effects meta-analysis with a relative risk, subgroups and meta-regression 
analyses were employed. 
Results: Overall, 9 studies met the inclusion criteria including 9,254 individuals in 
midlife with PTSD and 6,852 general population controls.  The pooled MetS 
prevalence was 38.7% (95%CI=32.1%-45.6%; Q=52.1, p<0.001; N=9; n=9,673; age 
range=44-61years). Abdominal obesity was observed in 49.3% (95%CI=29.7%-
69.0%), hyperglycaemia in 36.1% (95%CI=18.8%-55.6%), hypertriglyceridemia in 
45.9% (95%CI=12.2%-81.9%), low high density-lipoprotein-cholesterol in 46.4% 
(95%CI=26.4%-67.0%) and hypertension in 76.9% (95%CI=67.9%-84.8). The MetS 
prevalence was consistently high across geographical regions, settings or populations 
(war veterans or not). Compared with matched general population controls, people 
with PTSD had an almost double increased risk for MetS (RR=1.82; 95%CI=1.72-
1.92; p<0.001). Most analyses were not statistically heterogeneous.   
Conclusions: MetS is highly prevalent in people with PTSD. Routine screening and 
multidisciplinary management of medical and behavioral conditions is needed. Future 
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research should focus on how cardio-metabolic outcomes are moderated by clinical 
and treatment characteristics and genetic factors. 
Key words: PTSD, metabolic syndrome, glucose, MetS, cardiovascular disease, 
lipids.  
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1. INTRODUCTION 
People with posttraumatic stress disorder (PTSD), experience an excess mortality rate 
two to three times higher than the general population [1-3]. Previous research has 
demonstrated that PTSD is associated with poor physical health [4], including the 
presence and severity of cardiovascular diseases (CVD), which predicts mortality 
independent of age, gender, and conventional risk factors [5]. To assist clinicians in 
identifying and treating patients at an increased risk of CVD, the concept of the 
metabolic syndrome (MetS) has been introduced. MetS is defined by a constellation 
of risk factors including central obesity, high blood pressure, low high-density 
lipoprotein (HDL) cholesterol, elevated triglycerides and hyperglycemia. In the 
general population, these clustered risk factors have been associated with the 
development of CVD and excess mortality [6-8]. Although several definitions have 
been proposed for MetS, the most commonly used are the Adult Treatment Panel III 
(ATP-III) and adapted ATP-III criteria (ATP-III-A) [9, 10] by the National 
Cholesterol Education Program (NCEP) and the International Diabetes Federation 
criteria (IDF) [11] by the World Health Organization (WHO) [12]. Current definitions 
for MetS are aimed at being easy to use in clinical settings and share similar 
diagnostic thresholds. However, the role of abdominal obesity is central to the IDF 
definition [11], with provision of ethnic specific thresholds for waist circumference, 
while central obesity is not a mandatory NCEP/ATP [9, 10] MetS criterion. As a 
prevalent condition and predictor of CVD across racial, gender, and age groups, MetS 
provides the opportunity to identify high-risk populations and prevent the progression 
of some major causes of morbidity and mortality [13].  
Despite the established link between the MetS and mental disorders such as 
schizophrenia [14-16], depression [17] and bipolar disorder [18], little research 
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appears to have considered the prevalence of MetS and its components among people 
with PTSD.  Specifically, one previous meta-analysis [19] 
 
attempted to quantify the 
risk of MetS among people with PTSD and they found that people with PTSD have an 
increased risk for developing MetS compared with the general population (odds ratio 
(OR) 1.37 (95%CI=1.03–1.82) (n=528). Whilst helpful, a range of important 
questions remains. Importantly little information is currently available documenting 
the prevalence of MetS and constituent components including the frequency of central 
obesity, high blood pressure, low high-density lipoprotein (HDL) cholesterol, elevated 
triglycerides and hyperglycemia.  Such information is important to establish an 
overview of the full metabolic risk profile of people with PTSD.  It is also important 
to understand whether the risk profile of those with PTSD is the same depending on 
gender, age and the severity of depression in order to detect high-risk groups in need 
of priority screening and treatment. The role of such potential moderators on the 
association between PTSD and MetS can be determined through the use of meta-
regression analysis. Similarly, it remains to be explored whether the MetS prevalence 
in people with PTSD differs between settings (inpatient, outpatient, community 
settings) and populations (e.g. veterans) and between those who are taking 
antipsychotics, mood stabilizers or antidepressants and those who are not. If risk 
stratification were observed, it would help guide clinicians in monitoring and 
treatment decisions.  
Given the uncertainties outlined above and the pressing issue of premature 
mortality among people with PTSD attributable to CVD, we conducted a systematic 
review and meta-regression analysis to describe pooled prevalences of MetS and its 
components in people with PTSD taking into account variations in demographic and 
clinical variables and psychotropic medication use. Our secondary aim was to 
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compare the MetS prevalence in studies directly comparing persons with PTSD with 
age- and gender matched general population samples. 
 
2. METHODS 
2.1 Inclusion and Exclusion Criteria 
This systematic review was conducted in accordance with the MOOSE guidelines[20] 
and in line with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) standard [21] following a predetermined protocol prepared by 
the authors (Supplement 1). We included observational studies (cross-sectional, 
retrospective and prospective studies) in adults that fulfilled the following criteria: (a) 
a diagnosis of PTSD as diagnosed by the Diagnostic and Statistical Manual [22], the 
International Classification of Disease [23] or a validated instrument irrespective of 
clinical setting (inpatient, outpatient, community setting or mixed); and (b) a MetS 
diagnosis according to ATP-III [9], ATP-III-A [10], IDF [11] or WHO [12] standards, 
only allowing modification for body mass index cut-off of ≥30 instead of waist 
circumference. If we encountered a randomised control trial, we extracted the 
variables of interest at baseline. No language restrictions or time restrictions were 
placed upon the eligibility criteria of included articles. For estimation of the 
prevalence of MetS, we excluded studies with: (a) non-standardized diagnoses, (b) 
insufficient data for extraction of MetS frequencies, and (c) restriction to children 
and/or adolescents. In the case of multiple publications from the same study, only the 
most relevant paper or article was included. When required, we contacted the 
primary/corresponding authors of potential studies to (a) confirm eligibility, and (b) 
acquire the variables of interest if they were not available in the publication.  Authors 
of articles were contacted up to two times over a 3-week period.   
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2.2 Search Criteria, Study Selection and Critical Appraisal 
Two independent authors (SR, DV) searched Medline, PsycARTICLES, Embase and 
CINAHL from database inception to February 1
st
, 2015. Key words used were 
“metabolic syndrome” AND “posttraumatic stress disorder” in the title, abstract or 
index term fields. Manual searches were also conducted using the reference lists from 
recovered articles and the meta-analysis
 
of Bartoli et al. [19]. After the removal of 
duplicates, both reviewers screened the titles and abstracts of all potentially eligible 
articles. Both authors applied the eligibility criteria, and a list of full text articles was 
developed through consensus. The two reviewers then considered the full texts of 
these articles and the final list of included articles was reached through consensus. A 
third reviewer (BS) was available for mediation throughout this process. 
Methodological appraisal was performed according to PRISMA standards [21], 
including evaluation of bias (confounding, overlapping data, publication bias). 
Publication bias was tested using the Egger’s regression method [24] and Begg-
Mazumdar test [25], with a p-value <0.05 suggesting the presence of bias. In addition, 
a funnel plot was created, in which the study-specific effect estimates are displayed in 
relation to the standard error in order to assess the potential presence of publication 
bias.  
  
2.3 Statistical Analyses 
We pooled individual study data using DerSimonian-Laird proportion method [26] 
with StatsDirect. Due to anticipated heterogeneity, a random effects meta-analysis 
was employed. We calculated the relative risk (RR) of MetS and its components 
between people with PTSD and matched general population control groups, also only 
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using data from studies in which they were directly compared. We conducted several 
meta-regression analyses (if N≥3) to investigate potential moderators (age, percentage 
males, major depression disorder comorbidity prevalence, prevalence of those 
receiving antipsychotic treatment, smoking prevalence, hostile personality or not) 
with Comprehensive Meta Analysis (version 3).  
 
3. RESULTS 
3.1 Search Results and Included Participants 
Our search yielded 752 publications of which nine [27-35] met inclusion criteria 
(Figure 1). The list of excluded studies (with reasons) is presented in Supplement 2. 
The final sample comprised 9,673 unique persons in midlife with PTSD (of which 
8,617 (89%) were men). Sample sizes of included studies ranged from 33 to 8,999 
participants. Mean age was 53 years (range=44-61 years), 33.9% (SD 17.9, N=3) of 
the participants were currently employed and 39.3% (SD 25, N=3) also had major 
depressive disorder. Only two studies (n=161) reported smoking frequencies with 
40.5% of participants identified as smokers (95% confidence interval (CI)=5.9%-
82.1%; Cochran Q (Q)=31.1, p<0.001).  
[Insert Figure 1 about here] 
 
3.2 Prevalence of Metabolic Syndrome among people with PTSD 
It was possible to pool data from 9 unique studies which established the estimated 
weighted mean prevalence of MetS for PTSD of 38.7% (95%CI=32.1%-45.6%; 
Q=52.1, p<0.001; N=9; n=9,673). The funnel plot was broadly symmetrical 
(Supplement 3) and both the Begg-Mazumdar (Kendall's tau b=0.44, p=0.12) and 
Egger test (bias=0.80 (95%CI=-1.84 to 3.44; p=0.50) indicated no evidence 
publication bias.   
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3.3 Individual Metabolic Abnormalities among people with PTSD 
Three studies [28, 32, 35] reported on obesity frequency defined as waist 
circumference (>102cm in males and >88cm in females (ATP-III or ATP-III-A), 
while none of the studies reported the obesity frequency following the ethnicity-
specific IDF-criteria. Overall, the proportion of people with PTSD with abdominal 
obesity by the ATP definitions was 49.3% (n=194; 95%CI=29.7%-69.0%; Q=14.8, 
p<0.001). It was possible to pool data from 3 studies studies [28, 32, 35] to establish 
that the prevalence of hyperglycemia was 36.1% (N=3, n=194; 95%CI=18.8%-55.6%; 
Q=14.0, p<0.001). Hypertriglyceridemia was present in 45.9% (N=3, n=194; 
95%CI=12.2%-81.9%; Q=55.1, p<0.001)
 
[28, 32, 35];  low high-density-lipoprotein 
(HDL)-cholesterol was present in 46.4% (N=3, n=194; 95%CI=26.4%-67.0%; 
Q=16.2, p<0.001) [28, 32, 35] [27, 31, 34] and hypertension was present in 76.9% 
(N=2; n=93;  95%CI=67.9%-84.8%; Q=0.49, P=0.48) [28, 32].  
 
3.4 Subgroup analyses and Predictors of Metabolic Syndrome  
The pooled MetS prevalence in Europe (Bosnia-Herzegovina) was 39.6% (N=3; 
n=265; 95%CI=32.7%-46.7%; Q=2.81, P=0.24) [28, 33, 34] which was similar to 
rates reported in North-America (USA) (38.6%; N=6; n=9,408; 95%CI=29.0%-
48.6%; Q=47.1, P<0.001) [27, 29-32, 35]; z=1.47, p=0.14) with data on other 
geographical regions or countries not available. Similar rates of MetS prevalence in 
inpatients (N=2) [33, 34] or mixed settings (N=1)[27] combined was 34.8% (n=; 
95%CI=32.7%-46.7%; Q=2.81, P=0.24), while in outpatients or community patients it 
was 38.6% (N=6; n=9,408; 95%CI=29.0%-48.6%; Q=47.1, P<0.001) [28-32, 35] 
(z=1.37, p=0.16).  In the same way, we did not find significant differences between 
the prevalence of MetS in those studies only including veterans (44.0%; N=6; 
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n=9,493; 95%CI=13.1%-77.9%; Q=41.9, P<0.001) [27-29, 31, 33, 34] compared with 
studies in non-veterans or mixed samples (38.6%; N=3; n=180; 95%CI=29.0%-
48.6%; Q=47.1, P<0.001)[30, 32, 35] (z=-0.15, p=0.087). The exploratory meta-
regression analyses demonstrated that age variability between studies (N=7, n=9,467; 
coefficient=-0.006, 95%CI=-0.06 to 0.04, z=-0.24, p=0.81), differences in depression 
status (% with MDD) (N=3; n=285; coefficient=-0.417, 95%CI=-1.48to 0.57, z=-
0.81, p=0.41) and gender (% male) (N=9; n=9,673; coefficient=0.56, 95%CI= -0.50 to 
1.73 z=0.96, p=0.34) did not moderate the variability in MetS prevalence at study 
level. There was insufficient data to explore other potentially relevant moderators 
(e.g., psychotropic medication use, personality factors, lifestyle habits).   
 
3.5 Relative Risk (RR) of MetS and Metabolic Abnormalities in Persons with 
PTSD Compared with Age- And Gender Matched General Population Controls 
Four studies [27, 28, 30, 34] provided data on MetS prevalences in age and gender-
matched healthy control subjects. In a pooled relative risk meta-analysis, compared 
with general population controls (n=6,852; 21,51%, 95% CI = 17.7 to 25.57, Q= 5.1, 
p=0.1) persons with PTSD (n=9,254; 36.39%, 95% CI = 31.32 to 41.62, Q=5.9, 
==0.1) had significantly increased risk of MetS (RR=1.82; 95%CI=1.72-1.92; 
p<0.001; Q=2.43, p=0.48) (Figure 2).  
[Insert Figure 2 about here] 
 
4. DISCUSSION 
In total, 38.7% (95% CI=32.1%-45.6%) of the included PTSD population had MetS 
and the relative risk for MetS was almost two times higher than in age- and gender 
matched general population controls (RR=1.82; 95%CI=1.72-1.92; p<0.001). 
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Moreover, the MetS prevalence was consistently high across geographical regions, 
clinical settings or population groups (war veterans or not).  For the first time we 
found particularly high rates of abdominal obesity (49.3%, 95%CI=29.7%-69.0%;), 
hypertension (76.9%, 95%CI=67.9%-84.8%;) hypertriglyceridemia (45.9%, 
95%CI=12.2%-81.9%), hyperglycaemia (36.1%, 95%CI=18.8%-55.6%;) and low 
high density-lipoprotein (HDL)-cholesterol levels (46.4%, 95%CI=26.4%-67.0%).  
The high prevalence of MetS and its constituent risk factors established within the 
current meta-analysis are of considerable concern.   
Knowledge of factors associated with the highest MetS risk can help to 
identify individuals with PTSD at greatest need for intensive monitoring and 
intervention. Consistent with population studies [36, 37], we encountered no 
significant differences as a function of the number of women included within the 
studies possibly suggesting that men and women with PTSD require the same care. 
However, our findings should be interpreted with some caution due to the fact women 
were underrepresented across the 9 included studies (11%) and the studies reviewed 
did not report disaggregated MetS data by gender precluding direct comparison. In 
our exploratory meta-regression, we were not able to elucidate any significant 
moderators. This is almost certainly due to the paucity of data and the current meta-
regression analyses should be viewed as exploratory. The fact that age differences 
between studies was not associated with MetS prevalence may be due to the limited 
mean age variation across the included studies (range=44-61 years). We did not find a 
difference between different populations (e.g., veterans or not) however this should be 
interpreted with caution as the majority of the included studies recruited participants 
from a veteran background (N=6). Previous research [17] demonstrated that people 
with MDD are at an increased risk for MetS. At study level the variability in 
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percentage of people with PTSD with co-morbid MDD did not appear to explain the 
variability in MetS prevalence. Findings of individual studies were also inconsistent. 
While Jakovljević et al. [33] showed that PTSD among war veterans with MDD have 
a higher MetS risk than those without MDD, Weiss et al. [29] and Heppner et al. [31] 
indicated that MetS risk was not different for participants with comorbid PTSD and 
depression than for those with PTSD alone. The strongest evidence to date that the 
association of PTSD to incident cardio-metabolic diseases is independent of general 
distress is a recent study by Vaccarino et al. [38] in which it was found that 
adjustment for depression and other psychiatric diagnoses did not diminish the PTSD 
- cardiometabolic disease association. Future studies that focus on the unique 
association of PTSD with cardiometabolic disease risk mechanisms are however 
needed before any firm conclusions can be made. 
 
5. Future Research 
The current meta-analysis provides some indications for future research. First, since 
antipsychotic medications are increasingly used as off-label treatments for PTSD [39] 
and as an adjunctive treatment for co-morbid MDD [40], research on the underlying 
mechanisms for the development of metabolic abnormalities after pharmacotherapy 
initiation is needed. Future studies should examine as well more in detail whether 
antidepressants or mood stabilizers significantly modulate MetS risk. For example, 
previous studies [41, 42] found that some antidepressants may, in some 
circumstances, reduce hyperglycemia, normalize glucose homeostasis and also 
increase insulin sensitivity, whereas others, including tricyclic antidepressants, may 
exacerbate glycemic dysfunction or have little effect on glucose homeostasis [43, 44]. 
Second, the pathophysiology underlying the association between PTSD and MetS is 
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complex and not well understood, requiring further investigation [45]. Emerging 
evidence
 
suggests that both share pathophysiological features, including 
hypothalamic–pituitary–adrenal (HPA) and sympathoadrenomedullary dysfunction 
[46, 47], inflammation [48], common genetic links and epigenetic interactions [49, 
50]. Third the extent to which traumatic experiences associated with physical injury 
may moderate associations between PTSD and MetS need to be examined, 
particularly in relation to compromised function of the endocrine organs. 
Additionally, traumatic experience co-incident with central nervous system damage 
responsible for impulse control and daily life functioning, such as might occur in 
traumatic brain injury, may have adverse effects on the development of MetS through 
poor lifestyle. However, psychiatric comorbidity may also have a pivotal role and 
requires careful consideration. Fourth, it might be that a cumulative long-term effect 
of poor health behaviors places people with PTSD at the greatest risk for cardio-
metabolic disorders, more so than the psychiatric diagnosis per se. People with PTSD 
are more likely than the general population to have unhealthy lifestyle behaviors, such 
as being sedentary [51], smoking [52], alcohol and substance abuse [53], and having 
diets that are high in saturated fats and refined sugars [54], while low in fruit [55], 
placing them at higher risk for MetS and CVD than the general population. Future 
research should comprehensively assess MetS risk factors and evaluate lifestyle 
interventions. Previous research [56] demonstrated that a 12-week exercise 
programme in addition to usual care reduces PTSD and depressive symptoms, while 
decreasing waist circumference, improving sleep quality, and reducing sedentary 
time. Finally, long-term follow-up is required to accurately document the emergence 
of more distal outcomes, such as diabetes, ischemic heart disease, medical costs, and 
premature mortality.  
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6. Limitations  
Whilst the current meta-analysis is a first to investigate the prevalence of MetS and its 
constituents in people with PTSD conducted to date, we should acknowledge that 
variables such as psychotropic medication use, trauma exposure, time since exposure 
and diagnosis, personality factors (e.g. level of hostility) and lifestyle habits were not 
reported or were insufficiently reported or controlled for in most available studies.  In 
addition, the low number of studies that have documented MetS within PTSD samples 
to date resulted in limited numbers of participants and studies available for review. 
Nevertheless allowing for these caveats, the results of the current study provide a 
unique insight in the MetS risk among people with PTSD. Given the predictive 
accuracy of MetS for mortality and that CVD appears to contribute to a significant 
amount of the excess premature mortality among people with PTSD, the results of the 
present study are of clinical relevance and concern.   
 
7. Conclusions 
The current meta-analysis demonstrates that Metabolic Syndrome and its constituent 
components are highly prevalent amongst individuals identified with PTSD, who are 
almost twice as likely to have MetS compared to age and sex matched controls. The 
findings underscore the need for a multidisciplinary approach to assessment for 
patients presenting with PTSD that includes a focus on physical health as well as 
psychiatric symptoms. Treatment facilities should provide lifestyle interventions. 
Future research should focus on how cardio-metabolic outcomes are moderated by 
clinical and treatment characteristics and genetic factors.  
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Figure 1. Flow diagram for the search strategy 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
  
Records screened after duplicates and 
irrelevant papers were removed 
(n=27) 
Records excluded on title / abstract 
level  
(n=5) 
Reasons: review (n=5) 
Full-text articles assessed for 
eligibility  
(n=22) 
 
Records identified through database 
searching (n=752) 
-PsycARTICLES: n=711 
-Embase (major focus): n=19 
-Medline: n=19 
- CINAHL: n=3 
 
Additional records identified through other 
sources (n=1) 
Full-texts excluded with reasons  
(n=12) 
Reasons: overlap with included papers 
(n=7), not on Mets prevalence (n=3), no 
MetS prevalence obtained (n=3) 
Full-text articles included in the 
meta-analysis  
(n=9) 
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Figure 2. Relative risk meta-analysis plot (random effects) (n=4) 
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Table 1. Details of the included studies 
Ref
Nr. 
First 
Author 
(year) 
Country Participa
nts 
MetS 
criteri
um 
Mets 
prevale
nce 
Prevalence MetS 
Criteria  
MetS 
prevale
nce 
Control
s* 
27. Ahmadi 
2014 
USA 8,999 
Veterans 
versus 
6,587 
controls; 
90% male; 
58±15 
years 
ATP 
III 
34.8% / 19% 
28. Babic 
2013 
Bosnia 
Herzego
vina 
60 male 
Veterans 
versus 60 
male 
controls; 
49.6±10.8
years 
ATP 
III 
48.3% WC=58.3%;BP=75%;HD
L=31.7%; 
TG=40.0%;FG=33.3% 
25% 
29. Weiss 
2011 
USA 46 with 
current 
PTSD; 
30.4% 
male; 
43.7±11.0 
years 
ATP-
III-A 
47.8% / / 
30. Linville 
2011 
USA 90 
repatriated 
male 
prisoners 
of war 
(Vietnam-
era) with 
PTSD 
versus 60 
combat 
experience
d male 
aviators 
without 
PTSD; 
mean age 
entire 
sample: 61 
years 
ATP-
III-A 
(modifi
ed)  
30.0% / 23% 
31. Heppne
r 2009 
USA 139 
Veterans 
(Gulf-
War) with 
at least 
moderate 
severity 
PTSD; 
entire 
WHO 
ATP-
III-A 
43% / / 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
WWC= waist circumference, BP=blood pressure, HDL=high-density lipoproteins cholesterol, 
TG=triglycerides, FG=fasting glucose 
 
sample: 
92% male 
(76% 
White, 
19% 
Black); 
51.5±9.0 
years 
32. Jin 
2009 
USA 33 PTSD 
persons 
with 
psychotic 
symptoms; 
88% male; 
59.7±10.5 
years  
ATP-
III-A 
72% WC=61%;BP=81%;HDL
=72%; TG=61%;FG=58 
/ 
33. Jakovlj
evic 
2008 
Bosnia 
Herzego
vina 
100 male 
Combat 
Veterans; 
47.4±10.8
years 
ATP 
III 
35% / / 
34. Maslov 
2009 
Bosnia 
Herzego
vina 
105 
inpatients 
(war 
veterans) 
with 
PTSD; 
54% male 
(75% 
White, 
25% 
Black) 
ATP 
III 
38.1% /  
35. Violanti 
2006 
USA 101 police 
officers 
ATP-
III-A 
16% WC=32% (m=38%, 
f=23%); HDL=38% 
(m=39%, f=35%); 
TG=15% (m=23%, 
f=3%); FG=22% 
(m=33%, f=5%) 
/ 
